Partners Iv Lpblair James C... Net Worth

The estimated Net Worth of Partners Iv Lpblair James C... is at least $261 Million dollars as of 30 June 2015. Partners C owns over 20,470 units of Glaukos stock worth over $260,746,330 and over the last 9 years Partners sold GKOS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Partners C GKOS stock SEC Form 4 insiders trading

Partners has made over 1 trades of the Glaukos stock since 2015, according to the Form 4 filled with the SEC. Most recently Partners exercised 20,470 units of GKOS stock worth $156,596 on 30 June 2015.

The largest trade Partners's ever made was exercising 20,470 units of Glaukos stock on 30 June 2015 worth over $156,596. On average, Partners trades about 20,470 units every 0 days since 2015. As of 30 June 2015 Partners still owns at least 2,077,660 units of Glaukos stock.

You can see the complete history of Partners C stock trades at the bottom of the page.

Insiders trading at Glaukos

Over the last 11 years, insiders at Glaukos have traded over $300,254,118 worth of Glaukos stock and bought 17,376 units worth $317,262 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Gilbert H Kliman, and Jonathan Silverstein. On average, Glaukos executives and independent directors trade stock every 25 days with the average trade being worth of $8,240,079. The most recent stock trade was executed by Gilbert H Kliman on 9 September 2024, trading 3,000 units of GKOS stock currently worth $96,000.

What does Glaukos do?

glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde

Complete history of Partners C stock trades at Glaukos

Glaukos executives and stock owners

Glaukos executives and other stock owners filed with the SEC include:

• Thomas Burns,
  President, Chief Executive Officer, Director
• Chris Calcaterra,
  Chief Operating Officer
• Joseph Gilliam,
  Chief Financial Officer, Senior Vice President - Corporate Development
• Thomas William Burns,
  Chairman, CEO & Pres
• Joseph E. Gilliam,
  CFO & Sr. VP of Corp. Devel.
• Chris M. Calcaterra,
  Chief Operating Officer
• William Link,
  Independent Chairman of the Board
• Marc Stapley,
  Independent Director
• Mark Foley,
  Independent Director
• Aimee Weisner,
  Independent Director
• David Hoffmeister,
  Independent Director
• Gilbert Kliman,
  Director
• L. Jay Katz,
  Chief Medical Officer
• L. Jay Katz M.D., FACS,
  Chief Medical Officer
• David S. Haffner,
  Sr. VP of New Technologies
• Michele M. Allegretto,
  Sr. VP of HR
• Diana A. Scherer,
  VP of Compliance & Deputy Gen. Counsel
• Diane W. Biagianti,
  Sr. VP & Gen. Counsel
• Christopher William Lewis,
  Director of Investor Relations, Corp. Strategy & Devel.
• Dr. Mory Gharib Ph.D.,
  Co-Founder
• Advisors Llc Orbi Med Capit...,
  
• Advisors Llc Orbi Med Capit...,
  
• Equity Partners Iv Lp Montr...,
  
• Jonathan Silverstein,
  Director
• Richard L Harrison,
  Treasurer, CFO & Secretary
• Ventures I Llclubash Barbar...,
  
• Ventures I Llcversant Ventu...,
  
• Partners Iv Lpblair James C...,
  
• Iv Associates Lpblair James...,
  
• Viii Associates, L.P.Blair ...,
  
• Management Partners Ix, Llc...,
  
• Healthcare V, Lpfhm V, Llc ...,
  
• Ventures I Llcversant Ventu...,
  
• Robert J More,
  Director
• Paul S Madera,
  Director
• Olav Bergheim,
  Director
• Ventures I Llcversant Ventu...,
  
• Partners Viii, L.P.Blair Ja...,
  
• Capital Associates Iii L.L....,
  
• Alex R. Thurman,
  SVP & CHIEF FINANCIAL OFFICER
• Tomas Navratil,
  CHIEF DEVELOPMENT OFFICER
• Leana Wen,
  
• Denice Torres,